Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 9.27 as of 2026-10-06T20:47:04.501Z.
Consensus retrieved: 2026-10-06T13:01:23.403Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:47:04.501Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a33e4fc03fe8b1d125149be729754f1b86c36cdbb4e683325413a64d01d7bda
Forward PE Ratio (9.27) = Dated Quote Price ($231.39) / Consensus Forward EPS ($24.95)
FORWARD PE RATIO
9.27
SECTOR MEDIAN · HEALTHCARE
19.79
median of 190 covered companies
CURRENT VS SECTOR MEDIAN
-53.15%
vs the sector median at left
Jazz Pharmaceuticals plc
Market Cap
$14.54B
Forward PE Ratio
9.27
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | $14.54B | 9.27 |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 20.60 |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 16.61 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | 26.87 |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | N/A |
| Solventum Corporation (SOLV)vs › | $15.07B | 12.15 |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | N/A |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | N/A |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 13.04 |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | N/A |
Trailing P/E
15.8
reported TTM EPS
Forward P/E
9.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $24.95 implies +70.5% EPS growth vs the reported trailing $14.63.
At the dated quote price of $231.39, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $24.95 | $23.74 – $26.44 | 11 | 9.3x |
| 2027-12-31 | $25.90 | $23.13 – $30.93 | 11 | 8.9x |
| 2028-12-31 | $28.91 | $22.94 – $36.44 | 6 | 8.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
